Healthy VolunteersPhase 1NCT04252417
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
A Phase 1 study testing MD1003 in people with Healthy Volunteers and Hepatic Impairment of Moderate Child Pugh Category, run by MedDay Pharmaceuticals SA at 3 sites in 2 countries.
Trial summary
This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in hepatic impaired patients and healthy subjects with normal hepatic function. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers, Hepatic Impairment of Moderate Child Pugh Category
- What is being tested?
- MD1003
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 11 Oct 2019to 17 Mar 2020
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For eligibility into the trial, subjects and patients must meet all the following inclusion criteria:
- Male or female subjects, aged 18 to 75 years inclusive;
- Females participating in this study must be of non-childbearing potential or using acceptable contraception for the full duration of the study and for 1 month after the end of treatment, as described below:
- Cessation of menses for at least 12 months due to ovarian failure;
- Surgical sterilization such as bilateral oophorectomy, hysterectomy, or medically documented ovarian failure;
- Using an acceptable effective non-hormonal method of contraception (bilateral tubal occlusion, vasectomized partner or intra-uterine device, sexual abstinence, male or female condom with spermicide);
Show all 34Show fewer
- Negative serum pregnancy test at screening (if applicable);
- Normal renal function according to the age
- Non-smoker subject or smoker of not more than 5 cigarettes a day;
- Signing a written informed consent prior to selection;
- Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
- For hepatic impaired patients:
- Hepatic impairment of moderate Child Pugh category determined at screening (Class B: 7 to 9 points);
- Stable Hepatic dysfunction e.g. no clinical significant change in disease status within the last 30 days documented by recent medical history, including no worsening of clinical signs of hepatic impairment or no worsening of total Bilirubin or Prothrombin time>50%.
- Stable treatment regimen or dose of medication
- Supine blood pressure ≤ 170/110 mmHg;
- Body Mass Index (BMI) between 20 and 34 kg/m² inclusive.
- For healthy subject with normal hepatic function:
- Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination);
- Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive and body weight (BW) not lower than 55kg;
- Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position:
- 90 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 145 mmHg,
- 50 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 90 mmHg,
- 45 bpm ≤ HR ≤ 90 bpm,
- Or considered NCs by investigators;
- Normal ECG recording on a 12-lead ECG at the screening visit:
- 120 < PR < 220 ms,
- QRS < 110 ms,
- QTcf ≤ 430 ms for male and < 450 ms for female,
- No sign of any trouble of sinusal automatism,
- Or considered NCs by investigators;
- Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator. In particular, the hepatic function should be considered as normal;
- Normal dietary habits;
- Matched to at least 1 hepatic impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).
Who cannot join
- Subjects or Patients meeting any of the following criteria will not be included into the trial:
- Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests);
- Subject/Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
- Subject/Patient who cannot be contacted in case of emergency;
- History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensitivity to the investigation product or its excipients (including lactose);
- Any medications intake within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study drug, or any medication that may result in induction or inhibition of microsomal enzymes;
Show all 40Show fewer
- Subject/Patient who is in the exclusion period of a previous study;
- Administrative or legal supervision;
- Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;
- Subjects/Patients who are pregnant or breastfeeding. Subjects/Patients should not be enrolled if they plan to become pregnant during the time of study participation;
- Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day);
- History or presence of drug abuse;
- Positive results of screening for drugs of abuse;
- Intake of any food or any beverage containing grapefruit or grapefruit juice within 48h prior to the first dosing and the inability to stop such intake during the study.
- Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);
- General anesthesia within 3 months before administration;
- Major surgery within 28 days prior to inclusionor major surgery planned during the next 6 months.
- For hepatic impaired patients:
- Other underlying diseases that may alter Child Pugh components like metastatic cancer to the brain or peritoneal surface or cancer cachexia (hypoalbuminemia, encephalopathy, ascites);
- History of liver transplant;
- The patient has an acute exacerbation or unstable hepatic function, as indicated by worsening of clinical and/or laboratory signs of hepatic impairment, within the 4 weeks before study drug administration;
- Hepatocellular carcinoma confirmed by alpha-fetoprotein rate < 50 mg/dL no longer than 3 months before inclusion;
- Signs of encephalopathy (grade 1 to 4 e.g. moderate to severe);
- Presence of clinical ascites (slight to severe);
- Drug addict patients treated with methadone or buprenorphine;
- Presence of clinical ascites and/or pleural effusion. According to the investigator's judgement, small ascites radiologically detected but not clinically relevant could be accepted;
- Severe hepatic encephalopathy, (Grade > 2, portal systemic encephalopathy score);
- Recent history of gastrointestinal bleeding due to esophageal varices. According to the investigator's judgement, patient who had esophageal varices can be included if surgically treated by ligation, or sclerosis and with a prophylactic treatment by non-selective β-blockers (e.g., propranolol) and after checking by echography.
- History of hepatic cytolysis due to medication;
- Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.);
- History of febrile illness within 5 days prior to dosing;
- Any forbidden drug (as defined in protocol) intake during the 2 weeks or 5 half-lives of the drug preceding the first administration.
- For Healthy Subjects with normal hepatic function:
- Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, infectious or allergic disease
- Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting;
- Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position;
- Inability to abstain from intensive muscular effort;
- History or presence of alcohol abuse (alcohol consumption > 40 grams/day);
- Any drug intake (except paracetamol 3g/d) during the 2 weeks or 5 half-lives of the drug preceding the first administration;
- Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Trial locations and contacts
3 sites in 2 countries.
3 sites in 2 countries
Hungary2 sites
DRC Drug Research Center Ltd.
Balatonfüred, 8231
Clinical Research Units Hungary Ltd.
Miskolc, 3528
About this study
Official title: Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function
This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in hepatic impaired patients and healthy subjects with normal hepatic function.
The planned enrollment is 16 subjects (8 impaired patients and 8 healthy subjects).
Read the detailed description
The study is a multicentric, open label, phase I, two arms study to compare pharmacokinetics of MD1003 after a single oral dose of MD1003 100 mg in eight (8) healthy male/female subjects and eight (8) male/female patients of moderate Child Pugh category. Healthy subjects and patients will receive a single oral dose of MD1003 100 mg. The healthy subjects will match with impaired hepatic function patients on ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).
Participants will be admitted into the Clinical Research Units (CRU) on Day-3. On the morning of Day 1, subjects will receive a single 100 mg oral dose of MD1003 following an overnight fast (i.e., at least 10 hours). Participants will be confined to the CRU until discharge on Day 8, with PK blood sample draws for measurement of MD1003 and its main metabolites being taken throughout the confinement (Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168h post dose). A Follow up post study visit will occur on Day 14 (± 2 days).
Adverse events (AEs), clinical laboratory evaluations, vital signs assessments, 12-lead electrocardiograms (ECGs), and physical examination (PE) findings will be monitored at Screening and at specified times during the study. All AEs will be recorded throughout the study (i.e., from signing of the Informed Consent Form until Study Completion).
The Study Completion is defined as the last subject's end-of-study assessment.
- Being tested
- MD1003
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MD1003Drug
Single oral dose administration of MD1003 at Day 1
| Study group | Role | What they receive |
|---|---|---|
| Patients with hepatic impaired function | Active comparator | 8 patients with hepatic impairment of moderate Child Pugh category Receives: Drug: MD1003 |
| Healthy subjects | Active comparator | Healthy volunteers will be matched with impaired hepatic function patients Receives: Drug: MD1003 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under curve from dosing time to last measurment (AUC (0-t)) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing tme to infinity (AUC(0-∞)) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Observed maximum plasma concentration (Cmax) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of concentration of MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of concentration of Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of concentration of Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Secondary outcomes (20)
Measurement of plasma elimination half-life (t1/2) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of apparent volume of distribution (Vd/F) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of apparent clearance (CL/F) for MD1003
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing time to last measurment (AUC (0-t)) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing time to last measurment (AUC (0-t)) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing tme to infinity (AUC(0-∞)) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing tme to infinity (AUC(0-∞)) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Observed maximum plasma concentration (Cmax) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Observed maximum plasma concentration (Cmax) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of plasma elimination half-life (t1/2) Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of plasma elimination half-life (t1/2) Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for Bisnorbiotin
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for Biotin sulfoxide
Blood samples will be collected
Measured: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2020
- Study start11 Oct 2019
- Primary completion17 Mar 2020
- Study completion17 Mar 2020
Why it stopped: Due to other Phase 3 trial failure to meet primary endpoint
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Open label, Parallel-group, Single oral dose
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- MedDay Pharmaceuticals SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Eurofins Optimed
- Responsible party
- Sponsor
- Investigators
- Yves Donazzolo, MD, Principal investigator, Eurofins Optimed
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04252417
- Sponsor's protocol ID
- MD1003CT201901HI
- Other IDs
- 2019-002315-26, 2019
- Status last verified
- Jan 2020
- First submitted
- 31 Jan 2020
- Last updated
- 13 May 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function
- ClinicalTrials.gov ID
- NCT04252417
- Acronym / sponsor ID
- MD1003CT201901HI
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Due to other Phase 3 trial failure to meet primary endpoint
- Enrolment
- 15 participants (actual)
- Lead sponsor
- MedDay Pharmaceuticals SAIndustry (pharma, biotech, devices)
- Collaborators
- Eurofins Optimed
- Study start
- 11 Oct 2019 (actual)
- Primary completion
- 17 Mar 2020 (actual)
- Study completion
- 17 Mar 2020 (actual)
- First posted
- 5 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in hepatic impaired patients and healthy subjects with normal hepatic function.
The planned enrollment is 16 subjects (8 impaired patients and 8 healthy subjects).
Detailed description
The study is a multicentric, open label, phase I, two arms study to compare pharmacokinetics of MD1003 after a single oral dose of MD1003 100 mg in eight (8) healthy male/female subjects and eight (8) male/female patients of moderate Child Pugh category. Healthy subjects and patients will receive a single oral dose of MD1003 100 mg. The healthy subjects will match with impaired hepatic function patients on ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).
Participants will be admitted into the Clinical Research Units (CRU) on Day-3. On the morning of Day 1, subjects will receive a single 100 mg oral dose of MD1003 following an overnight fast (i.e., at least 10 hours). Participants will be confined to the CRU until discharge on Day 8, with PK blood sample draws for measurement of MD1003 and its main metabolites being taken throughout the confinement (Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168h post dose). A Follow up post study visit will occur on Day 14 (± 2 days).
Adverse events (AEs), clinical laboratory evaluations, vital signs assessments, 12-lead electrocardiograms (ECGs), and physical examination (PE) findings will be monitored at Screening and at specified times during the study. All AEs will be recorded throughout the study (i.e., from signing of the Informed Consent Form until Study Completion).
The Study Completion is defined as the last subject's end-of-study assessment.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Open label, Parallel-group, Single oral dose
| Arm | Type | Receives |
|---|---|---|
| Patients with hepatic impaired function | Active comparator | Drug: MD10038 patients with hepatic impairment of moderate Child Pugh category |
| Healthy subjects | Active comparator | Drug: MD1003Healthy volunteers will be matched with impaired hepatic function patients |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (34 listed)
- For eligibility into the trial, subjects and patients must meet all the following inclusion criteria:
- Male or female subjects, aged 18 to 75 years inclusive;
- Females participating in this study must be of non-childbearing potential or using acceptable contraception for the full duration of the study and for 1 month after the end of treatment, as described below:
- Negative serum pregnancy test at screening (if applicable);
- Normal renal function according to the age
Key exclusion criteria (40 listed)
- Subjects or Patients meeting any of the following criteria will not be included into the trial:
- Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests);
- Subject/Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
- Subject/Patient who cannot be contacted in case of emergency;
- History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensitivity to the investigation product or its excipients (including lactose);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MD1003Single oral dose administration of MD1003 at Day 1 | Drug | Healthy subjects, Patients with hepatic impaired function |
Primary outcome
Area under curve from dosing time to last measurment (AUC (0-t)) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
Area under curve from dosing tme to infinity (AUC(0-∞)) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
Observed maximum plasma concentration (Cmax) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
Measurement of concentration of MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
Measurement of concentration of Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
Measurement of concentration of Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Blood samples will be collected
20 secondary outcomes
Measurement of plasma elimination half-life (t1/2) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of apparent volume of distribution (Vd/F) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of apparent clearance (CL/F) for MD1003
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing time to last measurment (AUC (0-t)) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing time to last measurment (AUC (0-t)) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing tme to infinity (AUC(0-∞)) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Area under curve from dosing tme to infinity (AUC(0-∞)) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Observed maximum plasma concentration (Cmax) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Observed maximum plasma concentration (Cmax) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of time to reach observed maximum plasma concentration (tmax) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of plasma elimination half-life (t1/2) Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of plasma elimination half-life (t1/2) Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of elimination rate constant (Kel) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for Bisnorbiotin
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Measurement of percentage of extrapolated AUCinf (%AUCextra) for Biotin sulfoxide
Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose
Results and safety
The study was stopped early (reason given: Due to other Phase 3 trial failure to meet primary endpoint). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2020.
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yves Donazzolo, MD principal investigator
Eurofins Optimed
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing MD1003 in people with Healthy Volunteers and Hepatic Impairment of Moderate Child Pugh Category, run by MedDay Pharmaceuticals SA at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 34 inclusion and 40 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 13 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Hungary, France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Due to other Phase 3 trial failure to meet primary endpoint). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under curve from dosing time to last measurment (AUC (0-t)) for MD1003 (time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2020; AzTrials last refreshed its copy on 6 Nov 2026.